drugset
Drugs / VRC01
last change Dec 2021 re-read 9 days ago

VRC01

also known as VRC-HIVMAB060-00-AB

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Institute of Mental Health (NIMH)

Trials 12

today NCT03208231 · Ph 1/2 NCT02797171 · Ph 1 NCT02664415 · Ph 2 NCT02568215 · Ph 2 NCT02591420 · Ph 1 NCT02716675 · Ph 2 NCT02599896 · Ph 1 NCT02411539 · Ph 1 NCT02463227 · Ph 1 NCT02256631 · Ph 1 NCT02140255 · Ph 1/2 NCT02165267 · Ph 1
20152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials · 1 met primary · 2 missed
Phase 1 NCT02797171 Mar 2017 → Jun 2019 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02591420 Apr 2016 → Mar 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 1 NCT02599896 Nov 2015 → Jul 2018 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02411539 Aug 2015 → Apr 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 1 NCT02463227 Aug 2015 → Mar 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary
Phase 1 NCT02256631 Jun 2015 → Jun 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02165267 Aug 2014 → Feb 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/22 trials · 1 missed
Phase 1/2 NCT03208231 Aug 2018 → Jun 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 1/2 NCT02140255 Jan 2015 → Jan 2028 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 23 trials · 3 missed
Phase 2 NCT02664415 Aug 2016 → Aug 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 2 NCT02568215 May 2016 → Mar 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 2 NCT02716675 Apr 2016 → Dec 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as VRC01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02716675 ↗
11

NCT02591420 ↗

NCT02599896 ↗

NCT02797171 ↗

NCT02568215 ↗

NCT02664415 ↗

NCT02411539 ↗

NCT02165267 ↗

NCT02140255 ↗

NCT03208231 ↗

NCT02463227 ↗

Show 1 more source
Known as VRC-HIVMAB060-00-AB “experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01)” NCT02411539 ↗
Action Inhibit “halting viral replication” PMID 31000477 ↗ Apr 2019
Modality Monoclonal antibody “VRC01 monoclonal antibody” NCT02140255 ↗
Route Intravenous “Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.” NCT02165267 ↗
Route Subcutaneous “Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.” NCT02165267 ↗